Pilot-study: Predicton of response on Lu177-radioligand therapy in metastatic prostate carcinoma by early serial PSA-value examinatio
- Conditions
- C61Malignant neoplasm of prostate
- Registration Number
- DRKS00013500
- Lead Sponsor
- niversitätsklinikum Freiburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 28
Inclusion Criteria
Metastatic, castration refractory prostate carcinoma,
Lu177-PSMA-617-radioligand therapy planned
Exclusion Criteria
No significant PSA-serum level = supposingly no PSA expression of tumor
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome is reached by determination of PSA-serum value on date of the control-examination 4 weeks after a therapy cycle
- Secondary Outcome Measures
Name Time Method